Oncology

Experimental combination therapy shows a significant survival advantage over chemotherapy alone in pancreatic cancer.

National Health Checkup finds that cancer beat out infectious diseases as the biggest concern.

Top news of the day from across the health care landscape.

New insights pave the way for future treatment developments of pancreatic ductal adenocarcinoma.

Although these interactions pose a threat to patients, pharmacists can play a large role in minimizing them.

Top news of the week in oncology, and cancer drug development.

New mouse study suggests that exposure to endocrine disrupting chemicals may cause resistance to tamoxifen therapy in some breast cancers.

Novel drug combined with gemcitabine chemotherapy shows promise

With few advancements in treatment options, a new immunotherapy treatment could lead to better outcomes in pancreatic cancer.

Top news of the day from across the health care landscape.

Dopamine receptor blockers found to inhibit pancreatic tumor growth.

Mice treated with drugs that block a dopamine receptor inhibited cancer growth.

Jonathan Van Lare, PharmD, director of Clinical Services at Pharmacy Advantage, discusses the impact of oncology medications and how specialty pharmacies can adjust.

New findings demonstrating differing mechanisms may contribute to a better understanding of acquired resistance to combination drug treatment in cancer.

High body mass index linked to 10 types of cancer, including cancers of the breast, bowel, esophageal, and womb.

Top news of the day from across the healthcare landscape.

Top news of the day from across the health care landscape.

Chemotherapy combined with immunotherapy found to destroy dormant cancer cells.

Chemotherapy alone leaves behind dormant cells, but when combined with immunotherapy, it can destroy most of the dormant cells.

HIF-2 inhibitors may be better tolerated and more effective in kidney cancer.

Bristol-Myers Squibb employees will cycle across the US to raise awareness for cancer research.

Inhibiting immune cells’ oxygen-sensing capability prevented lung metastasis in mice.

The median charge of treatment for a 6-day hospital stay totals $37,000 in young cancer patients in need of stem cell transplants.

Chromosomal instability may be a potential biomarker for cancer prognosis.

The revolutionary CRISPR/Cas9 gene editing tool can target and inactivate cancer mutations, leading to more personalized therapies for patients.

Autumn Bagwell, PharmD, BCPS, clinical pharmacist at Vanderbilt Specialty Pharmacy, discusses the components of an effective patient management program to optimize adherence.

Pembrolizumab (Keytruda) was previously granted Breakthrough Therapy Designation for advanced non-small cell lung cancer.

A Supplemental Biologics License Application was submitted for Keytruda for the treatment of lung cancer.